iTrack™

THE iTRACK™ MIGS PROCEDURE, KNOWN AS AB-INTERNO CANALOPLASTY, CAN RE-ESTABLISH THE OUTFLOW PATHWAY IN THE TREATMENT OF MILD-MODERATE GLAUCOMA

Performed via an ab-interno approach, iTrack™ is an atraumatic, tissue-sparing MIGS procedure that achieves excellent clinical outcomes while also preserving the viability of future treatment options. Based on the same principles as angioplasty, iTrack™ combines 360° catheterization and pressurized viscodilation of Schlemm’s canal to remove outflow resistance in the proximal and distal outflow system – thereby reducing intraocular pressure (IOP) and patient dependence on medications.

  • iTrack™ addresses all outflow pathway resistance points, including the collector channel ostia1,2
  • iTrack™ is a tissue sparing procedure with no physiological changes 
  • iTrack™ does not leave behind stent or shunt 
  • iTrack™ offers an excellent safety profile7 — and overcomes the post-op complications seen with other MIGS such as stent misplacement and PAS3 – 6 
  • iTrack™ can be performed either in conjunction with cataract surgery or as a standalone procedure7

I view the angle as the new conjunctiva, because I want to manipulate it today – but I also want to preserve tissue. We all know that there’s not a single glaucoma procedure that lasts forever. I want to be able to come back and treat the patient again.”

iTRACK™ CAN TREAT ALL SITES OF OUTFLOW RESISTANCE IN THE CONVENTIONAL OUTFLOW SYSTEM — BOTH PROXIMAL AND DISTAL

With iTrack™ ab-interno canaloplasty you can target and treat the trabecular meshwork, Schlemm’s canal and the collector channels – without removing or damaging tissue, and without a permanent implant.

iTrack™ comprehensively treats outflow locations, which is why it is my first go-to MIGS procedure. I don’t have the diagnostic capability to know where the obstruction is located or what level of resistance exists, and so I like to start off with a MIGS that addresses everything.”

Not only does iTrack™ break the herniations that we see in the canal, but it also viscodilates. So, it’s really pushing out the entire distal channel and also opening up the trabecular meshwork.”

iTRACK™ CAN EFFECTIVELY REDUCE HERNIATIONS INTO THE COLLECTOR CHANNELS

Studies undertaken in human POAG eyes by Haiyan Gong, MD, PhD (University of Boston) have demonstrated that up to 90% of collector channels may be blocked with herniated trabecular meshwork tissue, resulting in reduced outflow facility.8

  1. During the iTrack™ procedure, 360° circumnavigation of Schlemm’s canal with the iTrack™ canaloplasty microcatheter pushes herniations out of the collector channel ostia to reduce outflow resistance.
  2. Following circumnavigation, 360° pressurized viscodilation with the iTrack™ canaloplasty microcatheter dilates the collector channel ostia to improve outflow.

iTRACK™ CAN INCREASE THE DIAMETER OF SCHLEMM’S CANAL

The dimensions of the lumen of Schlemm’s canal are smaller in POAG eyes, resulting in reduced outflow facility.2 This reduction in Schlemm’s canal dimensions may account for approximately half of the decrease in outflow facility observed in POAG eyes.9

  1. 360° circumnavigation of Schlemm’s canal with the iTrack™ canaloplasty microcatheter mechanically breaks adhesions within Schlemm’s canal to restore a more patent architecture to the canal. 
  2. 360° pressurized viscodilation dilates the canal to remove blockages and improve outflow facility. 

iTRACK™ IS THE WORLD’S FIRST CANALOPLASTY MICROCATHETER

iTrack™ is the world’s first canaloplasty microcatheter — and is the only canaloplasty microcatheter that enables you to customize the degree of viscodilation on an individual patient basis, maximizing patient outcomes. Despite measuring just 250 microns – the equivalent of several strands of hair – the iTrack™ comprises an infusion pathway for the delivery of OVD, a guide-wire that controls how the microcatheter tracks, and a fiber optic for illuminating the distal tip.

GREATER VOLUME OF OVD DELIVERY

The iTrack™ delivers more than 100 microliters of OVD over 360° of Schlemm’s canal* via a series of precise, surgeon-controlled aliquots. As observed via blanching of the episcleral veins immediately following the procedure4, iTrack™ ab-interno canaloplasty improves flow through the entire conventional outflow system, including the distal outflow system.

* Testing using a robotically controlled ViscoInjector™ with time-recording mass data to simulate the delivery of OVD over 360° of Schlemm’s canal. Data available upon request.


PRESSURIZED VISCODILATION

The iTrack™ canaloplasty microcatheter is the only device to deliver OVD into Schlemm’s canal via a patented, pressurized mechanism (Patent No. US7,967,772,B2) in order to stretch the trabecular meshwork and to create microperforations into the anterior chamber, and to push out herniations of the collector channel ostia.


SURGEON-CONTROLLED DELIVERY

With the iTrack™ canaloplasty microcatheter you can adjust the amount of OVD delivered based on the patency of Schlemm’s canal. 


INTELLIGENT NAVIGATION

A malleable yet rigid internal guide wire within the iTrack™ canaloplasty microcatheter minimizes the risk of creating an artificial pathway. It also enables you to push through herniations and to maneuver through tight areas of the canal.


PROPRIETARY ILLUMINATION

A proprietary illuminated fiber optic tip provides continuous location feedback and helps to safeguard against misdirection of the iTrack™ canaloplasty microcatheter into the suprachoroidal space or the collector channels.

In Vivo Aqueous Venography for Glaucoma

Modification to Ab Interno Canaloplasty (ABiC) and Gonioscopy Assisted Transluminal Trabeculotomy (GATT) that provides real time 360 degree in vivo aqueous v…

1. Stegmann R, Pienaar A, Miller D. Viscocanalostomy for open-angle glaucoma in black African patients. J Cataract Refract Surg. 1999;25(3):316 – 322.2. Grieshaber MC, Pienaar A, Olivier J, Stegmann R. Clinical evaluation of the aqueous outflow system in primary open-angle glaucoma for canaloplasty. Invest Ophthalmol Vis Sci. 2010;51(3):1498 – 1504.3. Gillman K, Mansouri K, Ambresin A, Bravetti G, Mermoud A. A Prospective Analysis of iStent Inject Microstent Implantation: Surgical Outcomes, Endothelial Cell Density, and Device Position at 12 Months. J Glaucoma. Volume 29, Number 8, August 2020.4. Shiba D, Hosoda S, Yaguchi S, Ozeki N, Yuki K, Tsubota K. Safety and Efficacy of Two Trabecular Micro-Bypass Stents as the Sole Procedure in Japanese Patients with Medically Uncontrolled Primary Open-Angle Glaucoma: A Pilot Case Series. J Ophthalmol. 2017; 2017: 9605461.5. Popovic M, Campos-Moller X, Saheb H, Ahmed IIK. Efficacy and Adverse Event Profile of the iStent and iStent Inject Trabecular Micro-bypass for Open-angle Glaucoma: A Meta-analysis. J Curr Glaucoma Pract 2018;12(2):67 – 84.
6. ElMallah MK, Seibold LK, Kahook MY et al. 12-Month Retrospective Comparison of Kahook Dual Blade Excisional Goniotomy with iStent Trabecular Bypass Device Implantation in Glaucomatous Eyes at the Time of Cataract Surgery. Adv Ther 36, 2515 – 2527 (2019).7. Gallardo MJ, Supnet RA, Ahmed IIK. Viscodilation of Schlemm’s canal for the reduction of IOP via an ab-interno approach. Clinical Ophthalmology. Vol 12. August 2018.8. Source: Cha ED, Xu J, Gong H. Variations in active areas of aqueous humor outflow through the trabecular outflow pathway. Presented at ARVO 2015.)9. Allingham RR, de Kater AW, Ethier CR. Schlemm’s canal and primary open angle glaucoma: correlation between Schlemm’s canal dimensions and ouflow facility. Exp Eye Research 1996;62:101 – 1

Send an enquiry

This website uses cookies to ensure you get the best experience on our website.
The cookies do not store any personalised information. Learn More